EarningsQ2 2026 Earnings Report
DE:LYF Q2 2026 EPS Results
Actual EPS<€0.01
Consensus EPS€0.01
Beat/MissMissed by -<€0.01
One Year Ago EPS<€0.01
DE:LYF Q2 2026 Revenue Results
Actual Revenue€29.19M
Expected Revenue€29.15M
Beat/MissBeat by +€33.82K
YoY Revenue Growth-0.83%
Earnings Announcement Details
QuarterQ2 2026
Date09/15/2026
TimeBefore Open
Conference CallTuesday, September 15, 2026
DE:LYF Upcoming Earnings
EKF Diagnostics Holdings's next earnings date is estimated for March 30, 2027, based on past reporting schedules.
Q2 2026 Earnings Call Audio
No earnings call audio is available for this earnings event.
Q2 2026 Earnings Slide Deck
No slide deck is available for this earnings event.
Q2 2026 Earnings Call Summary
Earnings Call Sentiment|Positive
The call was predominantly positive. Management reported improved gross margin, EBITDA and EPS, strong Life Sciences, BHB, contract manufacturing and fermentation growth, progress in the U.S. blood bank market, strategic investments, a strong balance sheet, and confidence in H2 recovery and FY2026 expectations. The main negatives were flat overall revenue, a 3% H1 Point-of-Care decline caused by delivery timing, lower free cash flow, higher administrative expenses, an exceptional lease charge, and an elevated H1 tax rate; management described these issues as timing-related, planned, or expected to improve.Company Guidance
Improved Profitability Despite Broadly Flat Revenue
H1 2026 group revenue was broadly flat at GBP 25 million, while gross margin strengthened by 3 percentage points to 53%, adjusted EBITDA increased 2.4% to GBP 5.9 million, and basic EPS rose nearly 26% to 0.54 pence from 0.43 pence.
Fourth Consecutive Year of First-Half EBITDA Growth
H1 adjusted EBITDA increased from GBP 4.4 million in 2023 to GBP 5.9 million in 2026, marking the fourth consecutive year of first-half growth. The adjusted EBITDA margin improved by 0.7 percentage points to 23.6%.
Strong Life Sciences Growth
Life Sciences revenue increased 8% to GBP 10 million from GBP 9.3 million, supported by 4% growth in BHB and strong execution in fermentation and contract manufacturing.
Contract Manufacturing and Fermentation Expansion
Contract manufacturing and fermentation revenue was reported as up 20% overall, with contract manufacturing later reported up 25% to GBP 1 million and fermentation up 40% to GBP 1.6 million. Growth was supported by new contract wins, organic growth within the existing business, and a strong H2 order book.
Point-of-Care Recovery Expected in H2
Point-of-Care revenue was GBP 15 million, down 3% because key tender closures shifted deliveries into H2 and production timing issues affected lactate deliveries. Management stated that both issues had been resolved, the order book was full, and the deferred revenue was expected to come through fully in H2.
Progress in U.S. Blood Bank Market
Three U.S. blood banks are now live with DiaSpect, with three more expected to come online in H2. EKF is actively negotiating with Blood Centers of America members for 2027 onboarding, and management estimated the addressable U.S. blood bank market at approximately $60 million, excluding the 40% already taken by the American Red Cross.
Blood Centers of America Agreement
The agreement signed with Blood Centers of America in March is supporting DiaSpect adoption and opening the U.S. blood bank opportunity, with management reporting improved visibility on the market.
Strong BHB Momentum
BHB growth year to date was stated as 9%, and H1 BHB growth with one distribution partner was 106%. That partner is expanding EKF's reach into more of the integrated delivery network market, and management expects BHB to deliver double-digit growth by year-end.
Hematology Product Progress
Hematology revenue was GBP 7.8 million and was described as relatively flat due to timing shifts, with visibility on larger tender orders including the Egyptian business. HemataStat II increased 9% as full availability returned, while Hemo Control remained the largest contributor and DiaSpect was a close second.
Flexible Diabetes Portfolio
Diabetes revenue was broadly flat overall, but Biosen grew significantly. Quo-Lab gained share from Quo-Test as reimbursement dynamics reset, demonstrating that the portfolio could flex with market changes rather than losing ground.
Strategic Progress Toward 2029 Targets
EKF reiterated its three strategic pillars: becoming number one in Point-of-Care hemoglobin, becoming number one in ketone testing across laboratory and Point-of-Care markets, and transforming Life Sciences into a standard CDMO. The 2029 targets are revenue above GBP 80 million and adjusted EBITDA above GBP 20 million.
Commercial Capacity Investments
The company continued investing in commercial capacity, recruited three commercial leaders covering the Americas, Europe, the Middle East and Africa, strengthened product management, and implemented a focused marketing strategy centered on high-growth opportunities and priority markets.
Capacity Expansion Investments
EKF is investing approximately GBP 4 million over the next 18 months to expand the Hemo Control production line by 30%, approximately GBP 2 million over the next 18 months for a new sensor production line, and additional amounts for next-generation analyzers, connectivity, and an ERP upgrade.
Beep Insights Acquisition Adds Digital Capability
The April 2026 acquisition of Beep Insights strengthened the sports performance portfolio by enabling users to manage lactate threshold testing through mobile phones, with additional AI elements being added.
Nexus Bioworks Rebrand
EKF is rebranding its Life Sciences contract manufacturing and fermentation offering as Nexus Bioworks to give the business a distinct identity and make its service offering clearer for clients, while retaining its more than 40 years of industry experience.
Simplified Operating Footprint
The company fully exited its Elkhart facility on June 30 and is now operating the Life Sciences division from one facility in South Bend.
Strong Balance Sheet and Capital Returns
EKF ended H1 with GBP 16 million of cash and total assets of GBP 82 million, supported by GBP 53.6 million of retained earnings. The share buyback has repurchased 23.5 million shares, approximately 5% of starting share capital, returning more than GBP 5.9 million at an average price of 25.2 pence per share.
Confidence in Full-Year Expectations
Management expressed strong confidence in a return to Point-of-Care growth in H2, continued BHB expansion, additional contract manufacturing opportunities, and delivery of FY2026 results in line with market expectations.
DE:LYF Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed